- Home
- SFL vs COLL Comparison
SFL vs COLL Comparison
Compare SFL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- COLL
- Stock Information
- Founded
- SFL 2003
- COLL 2002
- Country
- SFL Bermuda
- COLL United States
- Employees
- SFL N/A
- COLL N/A
- Industry
- SFL Marine Transportation
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- COLL Health Care
- Exchange
- SFL Nasdaq
- COLL Nasdaq
- Market Cap
- SFL 1.1B
- COLL 934.4M
- IPO Year
- SFL N/A
- COLL 2015
- Fundamental
- Price
- SFL $8.59
- COLL $29.14
- Analyst Decision
- SFL Strong Buy
- COLL Strong Buy
- Analyst Count
- SFL 1
- COLL 5
- Target Price
- SFL $13.00
- COLL $43.80
- AVG Volume (30 Days)
- SFL 1.0M
- COLL 304.8K
- Earning Date
- SFL 05-14-2025
- COLL 05-08-2025
- Dividend Yield
- SFL 12.59%
- COLL N/A
- EPS Growth
- SFL N/A
- COLL N/A
- EPS
- SFL 0.41
- COLL 1.25
- Revenue
- SFL $852,590,000.00
- COLL $664,283,000.00
- Revenue This Year
- SFL N/A
- COLL $20.00
- Revenue Next Year
- SFL $4.92
- COLL $3.74
- P/E Ratio
- SFL $21.15
- COLL $23.23
- Revenue Growth
- SFL 6.58
- COLL 17.17
- 52 Week Low
- SFL $6.78
- COLL $23.23
- 52 Week High
- SFL $14.42
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- SFL 55.68
- COLL 53.67
- Support Level
- SFL $8.41
- COLL $28.78
- Resistance Level
- SFL $8.64
- COLL $29.57
- Average True Range (ATR)
- SFL 0.24
- COLL 0.79
- MACD
- SFL -0.01
- COLL -0.03
- Stochastic Oscillator
- SFL 55.63
- COLL 36.56
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.